France’s Drug Reimbursement System
France’s current drug evaluation system involves two scales: one to determine absolute medical benefit (whether a drug or procedure will be reimbursed or not) and another additional medical benefit (which determines the rate of reimbursement.)
You may also be interested in...
France Seeks Stronger Cost-Effectiveness Tools To Lower Drug Prices, But Pan-European Bulk Buying May Come First
France’s drugs assessment agency wants simpler, stronger rules to evaluate the cost-effectiveness of new drugs. But changes to the country’s complex reimbursement system may be too slow to address immediate budget concerns, making pan-European bulk buying appear a more likely near-term solution.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.
Oncology and rare diseases dominate the industry pipeline, fuelled by science, regulatory tailwinds and high prices. But as the world grapples with coronavirus, and with heart disease still the top killer, can our systems fund treatments for more prevalent conditions?